Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60880

UPID:
SH21A_HUMAN

ALTERNATIVE NAMES:
Duncan disease SH2-protein; Signaling lymphocytic activation molecule-associated protein; T-cell signal transduction molecule SAP

ALTERNATIVE UPACC:
O60880; A8MSW0; O95383; O95384; O95385; O95386; Q6FGS6; Q9UNR0

BACKGROUND:
SH2 domain-containing protein 1A, also referred to as T-cell signal transduction molecule SAP, is crucial for SLAM family receptor regulation, impacting NK cell activation and neurotrophin receptor activity. Its involvement in multiple signaling pathways underscores its importance in immune response modulation and neurodevelopment.

THERAPEUTIC SIGNIFICANCE:
Given its association with Lymphoproliferative syndrome, X-linked, 1, characterized by extreme susceptibility to Epstein-Barr virus infections, the therapeutic exploration of SH2 domain-containing protein 1A offers a promising avenue for novel treatment modalities in immunodeficiency disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.